scispace - formally typeset
Search or ask a question

Showing papers by "Jo Vandesompele published in 2013"


Journal ArticleDOI
TL;DR: This report addresses known requirements for dPCR that have already been identified during this early stage of its development and commercial implementation and presents the Minimum Information for Publication of Quantitative Digital PCR Experiments guidelines.
Abstract: There is growing interest in digital PCR (dPCR) because technological progress makes it a practical and increasingly affordable technology. dPCR allows the precise quantification of nucleic acids, facilitating the measurement of small percentage differences and quantification of rare variants. dPCR may also be more reproducible and less susceptible to inhibition than quantitative real-time PCR (qPCR). Consequently, dPCR has the potential to have a substantial impact on research as well as diagnostic applications. However, as with qPCR, the ability to perform robust meaningful experiments requires careful design and adequate controls. To assist independent evaluation of experimental data, comprehensive disclosure of all relevant experimental details is required. To facilitate this process we present the Minimum Information for Publication of Quantitative Digital PCR Experiments guidelines. This report addresses known requirements for dPCR that have already been identified during this early stage of its development and commercial implementation. Adoption of these guidelines by the scientific community will help to standardize experimental protocols, maximize efficient utilization of resources, and enhance the impact of this promising new technology.

686 citations


Journal ArticleDOI
TL;DR: LNCipedia as discussed by the authors is a database for human long non-coding RNA (lncRNA) transcripts and genes, which contains 21 488 annotated human lncRNA transcripts obtained from different sources.
Abstract: Here, we present LNCipedia (http://www.lncipedia.org), a novel database for human long non-coding RNA (lncRNA) transcripts and genes. LncRNAs constitute a large and diverse class of non-coding RNA genes. Although several lncRNAs have been functionally annotated, the majority remains to be characterized. Different high-throughput methods to identify new lncRNAs (including RNA sequencing and annotation of chromatin-state maps) have been applied in various studies resulting in multiple unrelated lncRNA data sets. LNCipedia offers 21 488 annotated human lncRNA transcripts obtained from different sources. In addition to basic transcript information and gene structure, several statistics are determined for each entry in the database, such as secondary structure information, protein coding potential and microRNA binding sites. Our analyses suggest that, much like microRNAs, many lncRNAs have a significant secondary structure, in-line with their presumed association with proteins or protein complexes. Available literature on specific lncRNAs is linked, and users or authors can submit articles through a web interface. Protein coding potential is assessed by two different prediction algorithms: Coding Potential Calculator and HMMER. In addition, a novel strategy has been integrated for detecting potentially coding lncRNAs by automatically re-analysing the large body of publicly available mass spectrometry data in the PRIDE database. LNCipedia is publicly available and allows users to query and download lncRNA sequences and structures based on different search criteria. The database may serve as a resource to initiate small- and large-scale lncRNA studies. As an example, the LNCipedia content was used to develop a custom microarray for expression profiling of all available lncRNAs.

429 citations



Journal ArticleDOI
Stephen A. Bustin1, Vladimir Benes2, Jeremy A. Garson3, Jan Hellemans, Jim F. Huggett, Mikael Kubista, Reinhold Mueller, Tania Nolan, Michael W. Pfaffl4, Gregory L. Shipley, Carl T. Wittwer5, Peter Schjerling6, Philip J. R. Day7, Mónica Abreu8, Begoña Aguado9, Jean-François Beaulieu10, Anneleen Beckers11, Sara Bogaert11, John A. Browne12, Fernando Carrasco-Ramiro9, Liesbeth Ceelen, Kate L. Ciborowski13, Pieter Cornillie11, Stephanie Coulon11, Ann Cuypers14, Sara De Brouwer11, Leentje De Ceuninck11, Jurgen De Craene11, Hélène De Naeyer11, Ward De Spiegelaere11, Kato Deckers15, Annelies Dheedene11, Kaat Durinck11, Margarida Ferreira-Teixeira8, Annelies Fieuw11, Jack M. Gallup16, Sandra Gonzalo-Flores9, Karen Goossens11, Femke Heindryckx17, Elizabeth Herring10, Hans Hoenicka, Laura Icardi11, Rolf Jaggi18, Farzad Javad7, Michael Karampelias11, Frederick S. B. Kibenge19, Molly J. T. Kibenge19, Candy Kumps11, Irina Lambertz11, Tim Lammens20, Amelia Markey7, Peter Messiaen20, Evelien Mets11, Sofia Morais, Alberto Mudarra-Rubio9, Justine K. Nakiwala21, Hilde Nelis11, Pål A. Olsvik22, Claudina Perez-Novo20, Michelle Plusquin14, Tony Remans14, Ali Rihani11, Paulo Rodrigues-Santos8, Pieter Rondou11, Rebecca Sanders, Katharina Schmidt-Bleek23, Kerstin Skovgaard24, Karen Smeets14, Laura Tabera9, Stefan Toegel25, Tim Van Acker11, Wim Van den Broeck11, Joni Van der Meulen11, Mireille Van Gele11, Gert Van Peer11, Mario Van Poucke11, Nadine Van Roy11, Sarah Vergult11, Joris Wauman11, Marina Tshuikina-Wiklander26, Erik Willems27, Sara Zaccara28, Fjoralba Zeka11, Jo Vandesompele11 
TL;DR: Two surveys of over 1,700 publications whose authors use quantitative real-time PCR (qPCR) reveal a lack of transparent and comprehensive reporting of essential technical information.
Abstract: Two surveys of over 1,700 publications whose authors use quantitative real-time PCR (qPCR) reveal a lack of transparent and comprehensive reporting of essential technical information. Reporting standards are significantly improved in publications that cite the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines, although such publications are still vastly outnumbered by those that do not.

249 citations


Journal ArticleDOI
01 Jan 2013-Methods
TL;DR: Developing a framework for robust and unbiased assessment of curve analysis performance whereby various publicly available curve analysis methods were thoroughly compared using a previously published large clinical data set is aimed at.

226 citations


Journal ArticleDOI
TL;DR: Single mismatches located >5 bp from the 3' end have a moderate effect on qPCR amplification and can be tolerated, and this finding, together with the concentration independence for single mismatches and the complete blocking of the PCR reaction for ≥4 mismatches, can help to chart mismatch behavior inqPCR reactions and increase the rate of successful primer design for sequences with a high SNP density or for homologous regions of sequence.
Abstract: Background: Genome-sequencing studies have led to an immense increase in the number of known single-nucleotide polymorphisms (SNPs). Designing primers that anneal to regions devoid of SNPs has therefore become challenging. We studied the impact of one or more mismatches in primer-annealing sites on different quantitative PCR (qPCR)-related parameters, such as quantitative cycle (Cq), amplification efficiency, and reproducibility. Methods: We used synthetic templates and primers to assess the effect of mismatches at primer-annealing sites on qPCR assay performance. Reactions were performed with 5 commercially available master mixes. We studied the effects of the number, type, and position of priming mismatches on Cq value, PCR efficiency, reproducibility, and yield. Results: The impact of mismatches was most pronounced for the number of mismatched nucleotides and for their distance from the 3’ end of the primer. In addition, having ≥4 mismatches in a single primer or having 3 mismatches in one primer and 2 in the other was required to block a reaction completely. Finally, the degree of the mismatch effect was concentration independent for single mismatches, whereas concentration independence failed at higher template concentrations as the number of mismatches increased. Conclusions: Single mismatches located >5 bp from the 3’ end have a moderate effect on qPCR amplification and can be tolerated. This finding, together with the concentration independence for single mismatches and the complete blocking of the PCR reaction for >3 mismatches, can help to chart mismatch behavior in qPCR reactions and increase the rate of successful primer design for sequences with a high SNP density or for homologous regions of sequence.

157 citations


Journal ArticleDOI
03 Jan 2013-Oncogene
TL;DR: The results of this study point to miR-132 as a methylation-silenced miRNA with an antimetastatic role in PCa controlling cellular adhesion.
Abstract: Silencing of microRNAs (miRNAs) by promoter CpG island methylation may be an important mechanism in prostate carcinogenesis. To screen for epigenetically silenced miRNAs in prostate cancer (PCa), we treated prostate normal epithelial and carcinoma cells with 5-aza-2'-deoxycytidine (AZA) and subsequently examined expression changes of 650 miRNAs by megaplex stemloop reverse transcription-quantitative PCR. After applying a selection strategy, we analyzed the methylation status of CpG islands upstream to a subset of miRNAs by methylation-specific PCR. The CpG islands of miR-18b, miR-132, miR-34b/c, miR-148a, miR-450a and miR-542-3p showed methylation patterns congruent with their expression modulations in response to AZA. Methylation analysis of these CpG islands in a panel of 50 human prostate carcinoma specimens and 24 normal controls revealed miR-132 to be methylated in 42% of human cancer cases in a manner positively correlated to total Gleason score and tumor stage. Expression analysis of miR-132 in our tissue panel confirmed its downregulation in methylated tumors. Re-expression of miR-132 in PC3 cells induced cell detachment followed by cell death (anoikis). Two pro-survival proteins-heparin-binding epidermal growth factor and TALIN2-were confirmed as direct targets of miR-132. The results of this study point to miR-132 as a methylation-silenced miRNA with an antimetastatic role in PCa controlling cellular adhesion.

139 citations


Journal ArticleDOI
TL;DR: An miRNA signature associated with forskolin and ssUV treatment is established and the significant down- or upregulation of major pigmentation genes, after modulating miR-145 expression, suggests a key role for mi R-145 in regulating melanogenesis.

99 citations


Journal ArticleDOI
TL;DR: It is concluded that miR‐137 directly targets KDM1A mRNA in neuroblastoma cells, and activates cell properties consistent with tumor suppression, and Therapeutic strategies to re‐express miR•137 in neuro Blastoma could be useful to reduce tumor aggressiveness.
Abstract: Neuroblastoma is the most common extracranial solid tumor of childhood, and accounts for ∼15% of all childhood cancer deaths. The histone demethylase, lysine-specific demethylase 1 (KDM1A, previously known as LSD1), is strongly expressed in neuroblastomas, and overexpression correlates with poor patient prognosis. Inducing differentiation in neuroblastoma cells has previously been shown to down regulate KDM1A, and siRNA-mediated KDM1A knockdown inhibited neuroblastoma cell viability. The microRNA, miR-137, has been reported to be downregulated in several human cancers, and KDM1A mRNA was reported as a putative target of miR-137 in colon cancer. We hypothesized that miR-137 might have a tumor-suppressive role in neuroblastoma mediated via downregulation of KDM1A. Indeed, low levels of miR-137 expression in primary neuroblastomas correlated with poor patient prognosis. Re-expressing miR-137 in neuroblastoma cell lines increased apoptosis and decreased cell viability and proliferation. KDM1A mRNA was repressed by miR-137 in neuroblastoma cells, and was validated as a direct target of miR-137 using reporter assays in SHEP and HEK293 cells. Furthermore, siRNA-mediated KDM1A knockdown phenocopied the miR-137 re-expression phenotype in neuroblastoma cells. We conclude that miR-137 directly targets KDM1A mRNA in neuroblastoma cells, and activates cell properties consistent with tumor suppression. Therapeutic strategies to re-express miR-137 in neuroblastomas could be useful to reduce tumor aggressiveness.

98 citations


Journal ArticleDOI
13 Jun 2013-Oncogene
TL;DR: A novel integrated approach for analyzing DNA methylation coupled with miRNA and mRNA expression data sets identified 67 epigenetically regulated miRNAs in neuroblastoma, demonstrating the dynamic nature of the miRNA epigenome and identifying a remarkable network of miRNA/mRNA interactions that significantly contribute to neuroblast cancer pathogenesis.
Abstract: MicroRNAs (miRNAs) contribute to the pathogenesis of many forms of cancer, including the pediatric cancer neuroblastoma, but the underlying mechanisms leading to altered miRNA expression are often unknown. Here, a novel integrated approach for analyzing DNA methylation coupled with miRNA and mRNA expression data sets identified 67 epigenetically regulated miRNA in neuroblastoma. A large proportion (42%) of these miRNAs was associated with poor patient survival when underexpressed in tumors. Moreover, we demonstrate that this panel of epigenetically silenced miRNAs targets a large set of genes that are overexpressed in tumors from patients with poor survival in a highly redundant manner. The genes targeted by the epigenetically regulated miRNAs are enriched for a number of biological processes, including regulation of cell differentiation. Functional studies involving ectopic overexpression of several of the epigenetically silenced miRNAs had a negative impact on neuroblastoma cell viability, providing further support to the concept that inactivation of these miRNAs is important for neuroblastoma disease pathogenesis. One locus, miR-340, induced either differentiation or apoptosis in a cell context dependent manner, indicating a tumor suppressive function for this miRNA. Intriguingly, it was determined that miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA). Further biological studies of miR-340 revealed that it directly represses the SOX2 transcription factor by targeting of its 3'-untranslated region, explaining the mechanism by which SOX2 is downregulated by ATRA. Although SOX2 contributes to the maintenance of stem cells in an undifferentiated state, we demonstrate that miR-340-mediated downregulation of SOX2 is not required for ATRA induced differentiation to occur. In summary, our results exemplify the dynamic nature of the miRNA epigenome and identify a remarkable network of miRNA/mRNA interactions that significantly contribute to neuroblastoma disease pathogenesis.

89 citations


Journal ArticleDOI
21 Feb 2013-Oncogene
TL;DR: Evidence that murine neural crest progenitor cells can give rise to neuroblastoma upon transformation with MYCN or ALKF1174L is presented and indicates that neuroblastomas arise as their malignant progeny.
Abstract: Neuroblastoma is an embryonal tumor with a heterogeneous clinical course. The tumor is presumed to be derived from the neural crest, but the cells of origin remain to be determined. To date, few recurrent genetic changes contributing to neuroblastoma formation, such as amplification of the MYCN oncogene and activating mutations of the ALK oncogene, have been identified. The possibility to model neuroblastoma in mice allows investigation of the cell of origin hypothesis in further detail. Here we present the evidence that murine neural crest progenitor cells can give rise to neuroblastoma upon transformation with MYCN or ALK(F1174L). For this purpose we used JoMa1, a multipotent neural crest progenitor cell line, which is kept in a viable and undifferentiated state by a tamoxifen-activated c-Myc transgene (c-MycER(T)). Expression of MYCN or ALK(F1174L), one of the oncogenic ALK variants identified in primary neuroblastomas, enabled these cells to grow independently of c-MycER(T) activity in vitro and caused formation of neuroblastoma-like tumors in vivo in contrast to parental JoMa1 cells and JoMa1 cells-expressing TrkA or GFP. Tumorigenicity was enhanced upon serial transplantation of tumor-derived cells, and tumor cells remained susceptible to the MYC-inhibitor, NBT-272, indicating that cell growth depended on functional MYCN. Our findings support neural crest progenitor cells as the precursor cells of neuroblastoma, and indicate that neuroblastomas arise as their malignant progeny.

01 Jan 2013
TL;DR: The authors' analyses suggest that, much like microRNAs, many lncRNAs have a significant secondary structure, in-line with their presumed association with proteins or protein complexes, which may serve as a resource to initiate small- and large-scale lncRNA studies.
Abstract: Long non-coding RNAs (lncRNAs) constitute a large and diverse class of non-coding RNA genes. While several lncRNAs have been functionally annotated, the majority remains to be characterized. Different high-throughput methods to identify new lncRNAs have been applied in various studies resulting in multiple unrelated lncRNA datasets. Here, we present LNCipedia 2.0, the second version of our integrated database containing 32,198 annotated human lncRNA transcripts obtained from different sources. In addition to basic transcript information and gene structure, LNCipedia reports lncRNA secondary structure information, protein coding potential and microRNA binding sites. In version 2.0 we introduce a novel strategy to evaluate lncRNA protein-coding potential, based on automatic re-analysis of publicly available mass spectrometry data in the PRIDE database. We also report locus conservation of lncRNAs, assessed by means of positional conservation and order of the flanking protein coding genes. Finally, available literature on specific lncRNAs is linked and users can submit articles through a web interface. LNCipedia (http://www.lncipedia.org) is publicly available and allows users to query and download lncRNA sequences and structures based on different search criteria. The database may serve as a resource to initiate both small- and large-scale lncRNA studies.

Journal ArticleDOI
TL;DR: Functional evidence is found that miR-218, mainly expressed in the inner cell mass, regulates the NANOG expression in the bovine blastocyst in response to FGF signaling.
Abstract: Mammalian blastocyst formation is characterized by two lineage segregations resulting in the formation of the trophectoderm, the hypoblast, and the epiblast cell lineages. Cell fate determination during these early lineage segregations is associated with changes in the expression of specific transcription factors. In addition to the transcription factor-based control, it has become clear that also microRNAs (miRNAs) play an important role in the post-transcriptional regulation of pluripotency and differentiation. To elucidate the role of miRNAs in early lineage segregation, we compared the miRNA expression in early bovine blastocysts with the more advanced stage of hatched blastocysts. Reverse transcription-quantitative PCR-based miRNA expression profiling revealed eight upregulated miRNAs (miR-127, miR-130a, miR-155, miR-196a, miR-203, miR-28, miR-29c, and miR-376a) and four downregulated miRNAs (miR-135a, miR-218, miR-335, and miR-449b) in hatched blastocysts. Through an integrative analysis of matching miRNA and mRNA expression data, candidate miRNA-mRNA interaction pairs were prioritized for validation. Using an in vitro luciferase reporter assay, we confirmed a direct interaction between miR-218 and CDH2, miR-218 and NANOG, and miR-449b and NOTCH1. By interfering with the FGF signaling pathway, we found functional evidence that miR-218, mainly expressed in the inner cell mass, regulates the NANOG expression in the bovine blastocyst in response to FGF signaling. The results of this study expand our knowledge about the miRNA signature of the bovine blastocyst and of the interactions between miRNAs and cell fate regulating transcription factors.

Journal ArticleDOI
04 Jan 2013-PLOS ONE
TL;DR: F focal DNA copy number imbalances in neuroblastoma are indicated to be target genes that are implicated in MYCN signaling, possibly selected to reinforce MYCN oncogene addiction and serve as a resource for identifying new molecular targets for treatment.
Abstract: Neuroblastoma is an embryonic tumor arising from immature sympathetic nervous system cells. Recurrent genomic alterations include MYCN and ALK amplification as well as recurrent patterns of gains and losses of whole or large partial chromosome segments. A recent whole genome sequencing effort yielded no frequently recurring mutations in genes other than those affecting ALK. However, the study further stresses the importance of DNA copy number alterations in this disease, in particular for genes implicated in neuritogenesis. Here we provide additional evidence for the importance of focal DNA copy number gains and losses, which are predominantly observed in MYCN amplified tumors. A focal 5 kb gain encompassing the MYCN regulated miR-17∼92 cluster as sole gene was detected in a neuroblastoma cell line and further analyses of the array CGH data set demonstrated enrichment for other MYCN target genes in focal gains and amplifications. Next we applied an integrated genomics analysis to prioritize MYCN down regulated genes mediated by MYCN driven miRNAs within regions of focal heterozygous or homozygous deletion. We identified RGS5, a negative regulator of G-protein signaling implicated in vascular normalization, invasion and metastasis, targeted by a focal homozygous deletion, as a new MYCN target gene, down regulated through MYCN activated miRNAs. In addition, we expand the miR-17∼92 regulatory network controlling TGFs signaling in neuroblastoma with the ring finger protein 11 encoding gene RNF11, which was previously shown to be targeted by the miR-17∼92 member miR-19b. Taken together, our data indicate that focal DNA copy number imbalances in neuroblastoma (1) target genes that are implicated in MYCN signaling, possibly selected to reinforce MYCN oncogene addiction and (2) serve as a resource for identifying new molecular targets for treatment.

Journal ArticleDOI
01 Apr 2013-PLOS ONE
TL;DR: BCR triggering of CLL cells induces a transcriptional response of genes associated with BCR activation, enhanced cell cycle entry and progression, and it is suggested that part of the transcriptional profiles linked to IGHV mutation status observed in isolated peripheral blood are not cell intrinsic but rather secondary to in vivo BCR stimulation.
Abstract: Chronic lymphocytic leukemia (CLL) is a disease with variable clinical outcome. Several prognostic factors such as the immunoglobulin heavy chain variable genes (IGHV) mutation status are linked to the B-cell receptor (BCR) complex, supporting a role for triggering the BCR in vivo in the pathogenesis. The miRNA profile upon stimulation and correlation with IGHV mutation status is however unknown. To evaluate the transcriptional response of peripheral blood CLL cells upon BCR stimulation in vitro, miRNA and mRNA expression was measured using hybridization arrays and qPCR. We found both IGHV mutated and unmutated CLL cells to respond with increased expression of MYC and other genes associated with BCR activation, and a phenotype of cell cycle progression. Genome-wide expression studies showed hsa-miR-132-3p/hsa-miR-212 miRNA cluster induction associated with a set of downregulated genes, enriched for genes modulated by BCR activation and amplified by Myc. We conclude that BCR triggering of CLL cells induces a transcriptional response of genes associated with BCR activation, enhanced cell cycle entry and progression and suggest that part of the transcriptional profiles linked to IGHV mutation status observed in isolated peripheral blood are not cell intrinsic but rather secondary to in vivo BCR stimulation.

Journal ArticleDOI
TL;DR: This study evaluated the stability of various references during retinoic acid-induced (2 microM) differentiation of hES cells and found beta-2-microglobulin, ribosomal protein L13A and Alu repeats to be the most stable for this experimental set-up.
Abstract: Background Selecting stably expressed reference genes is essential for proper reverse transcription quantitative polymerase chain reaction gene expression analysis. However, this choice is not always straightforward. In the case of differentiating human embryonic stem (hES) cells, differentiation itself introduces changes whereby reference gene stability may be influenced.

Journal ArticleDOI
14 Aug 2013-PLOS ONE
TL;DR: This study evaluated the expression levels of 11 commonly used reference genes as internal controls for normalization of 19 experiments that include neuroblastoma, T-ALL, melanoma, breast cancer, non small cell lung cancer, acute myeloid leukemia (AML), prostate cancer, colorectal cancer, and cervical cancer cell lines subjected to various perturbations.
Abstract: Background Measuring messenger RNA (mRNA) levels using the reverse transcription quantitative polymerase chain reaction (RT-qPCR) is common practice in many laboratories. A specific set of mRNAs as internal control reference genes is considered as the preferred strategy to normalize RT-qPCR data. Proper selection of reference genes is a critical issue, especially in cancer cells that are subjected to different in vitro manipulations. These manipulations may result in dramatic alterations in gene expression levels, even of assumed reference genes. In this study, we evaluated the expression levels of 11 commonly used reference genes as internal controls for normalization of 19 experiments that include neuroblastoma, T-ALL, melanoma, breast cancer, non small cell lung cancer (NSCL), acute myeloid leukemia (AML), prostate cancer, colorectal cancer, and cervical cancer cell lines subjected to various perturbations.

01 Jan 2013
TL;DR: This study combines two genome-wide methylation discovery methodologies and is the most extensive validation study in neuroblastoma performed thus far to identify several novel prognostic DNA methylation markers and provide a basis for the development of a DNAmethylation-based prognostic classifier in Neuroblastoma.
Abstract: Accurate outcome prediction in neuroblastoma (NB), which is necessary to enable the optimal choice of risk-related therapy, remains a challenge. To improve NB patient stratification, this study aimed to identify prognostic tumor DNA methylation biomarkers. To identify genes silenced by promoter methylation, we first applied two independent genome-wide methylation screening methodologies to eight NB cell lines. Specifically, we used re-expression profiling upon 5-aza-2’-deoxycytidine (DAC) treatment and massively parallel sequencing after capturing with a methyl-CpG-binding domain (MBD-seq). Candidate methylation markers were selected from DAC-upregulated genes through a literature search and an upfront methylation-specific PCR (MSP) on 20 primary NB tumors, as well as through MBD-seq in combination with publicly available NB tumor gene expression data. This yielded 43 candidate biomarkers that were subsequently tested by high-throughput MSP on an independent cohort of 89 primary NB tumors that had been selected for risk classification and survival. Based on this analysis, methylation of KRT19, FAS, PRPH, CNR1, QPCT, HIST1H3C, ACSS3 and GRB10 was found to be associated with at least one of the classical risk factors, namely age, stage or MYCN status. Importantly, HIST1H3C and GNAS methylation was associated with overall and/or event-free survival. In conclusion, this study combines two genome-wide methylation discovery methodologies and is the most extensive validation study in NB performed thus far. We identified several novel prognostic DNA methylation markers and provide a basis for the development of a DNA methylation-based prognostic classifier in NB.

24 Oct 2013
TL;DR: Preclinical data are discussed here preclinical data that support the notion that nutlin drugs may offer therapeutic benefit for children with neuroblastoma, on condition that wild-type p53 is present.
Abstract: Neuroblastoma is one of the most common and most deadly childhood tumors. There is an unmet need to develop new therapeutic modalities for this malignancy that preferentially should be guided by our increasing knowledge of the biology of neuroblastoma. Proliferation and survival of neuroblastoma cells is critically dependent on suppression of the activity of the tumor suppressor protein p53, which is often mediated by increased activity of the MDM2 oncoprotein. Accordingly, small-molecule inhibitors of the interaction between MDM2 and p53 may provide a useful therapeutic option for the treatment of neuroblastoma by restoring the potent antitumor activity of wild-type p53. One of the most promising classes of selective inhibitors of the p53–MDM2 interaction are the nutlins, which have been extensively studied over the last years in several tumor types, including neuroblastoma. We discuss here preclinical data that support the notion that nutlin drugs may offer therapeutic benefit for children with neuroblastoma, on condition that wild-type p53 is present.

01 Jan 2013
TL;DR: It is necessary to select patients suitable for vaginal or laparoscopic preoperatively for blood donation based on prior history and once they provide informed consent for surgery, the likelihood of adverse events increases.
Abstract: doi:10.1182/blood-2003-06-2163Prepublished online August 28, 2003;2004 103: 229-235€€€€Anne De Paepe, Anne Hagemeijer and Frank SpelemanBloomfield, H. Berna Beverloo, Lucienne Michaux, Nicole Dastugue, Christian Herens, Nurten Yigit, Bruce Poppe, Jo Vandesompele, Claudia Schoch, Charlotta Lindvall, Krzysztof Mrozek, Clara D.€